Dr. William P. Dillon, D.O.
Infectious Disease (Infectious Disease Physician)
22101 Moross Rd, Professional Building 2, Suite 50
Detroit, MI 48236
- Medicare participating
At a glance
- Medical school
- Michigan State University College of Osteopathic Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 262
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Michigan State University College of Osteopathic Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
MI license 5101024487 -
Internal Medicine Physician
MI license 5101022383 · MI license 5101024487
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Henry Ford Health Hospital Detroit, MI
- Henry Ford Health West Bloomfield Hospital W Bloomfield, MI
Medical groups
- Henry Ford Health System (2,570 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 262
- Services billed
- 678
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 70 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 55 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 32 | 32 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 16 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Doxycycline Hyclate Other prescribers in Detroit, MI | 17 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Detroit, MI | 17 |
| Ciprofloxacin Hcl Other prescribers in Detroit, MI | 13 |
| Tivicay (dolutegravir sodium) | 11 |
| Tenofovir Disoproxil Fumarate | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $387 in total to this clinician.
| Astellas Pharma US Inc | $236 |
|---|---|
| Shionogi Inc | $111 |
| Paratek Pharmaceuticals, Inc. | $39.95 |
| Education | $276 |
|---|---|
| Food and Beverage | $111 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Aug 29, 2025 | Education in-kind | $87.00 |
| Astellas Pharma US Inc Jul 22, 2025 | Education in-kind | $79.99 |
| Astellas Pharma US Inc Oct 1, 2025 | Education in-kind | $69.00 |
| Paratek Pharmaceuticals, Inc. Apr 25, 2025 | Education NUZYRA · ANTIBIOTIC · in-kind | $39.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $119,315 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Su…
AstraZeneca Pharmaceuticals LP - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.